We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

High-Speed NanoPCR Technology Diagnoses COVID-19 in 20 Minutes with Zero False Positive and False Negative

By LabMedica International staff writers
Posted on 09 Dec 2020
Print article
Illustration
Illustration
A new high-speed nanoPCR technology for point-of-care (POC) diagnosis of COVID-19 can accurately diagnose the infection in less than 20 minutes, with zero false positive and false negative.

The nanoPCR technology developed by scientists at the Center for Nanomedicine (CNM) within the Institute for Basic Science (IBS; Seoul, Korea) can diagnose COVID-19 while retaining the accuracy of conventional reverse transcription polymerase chain reaction (RT-PCR) technology. The novel nanoPCR technology that can be used for the decentralized, POC diagnosis of COVID-19 uses the same underlying principle as the standard diagnosis method of RT-PCR to detect viral RNA, but also features a vast improvement in speed using hybrid nanomaterials and a miniaturized form factor which allows portability.

The research team utilized a magneto-plasmonic nanoparticle (MPN) that is comprised of magnetic material in its core and a gold shell that exhibits plasmonic effects. By applying MPNs to PCR, they developed 'nanoPCR' which greatly improves the speed of RT-PCR while retaining highly accurate detection. Plasmonic properties of MPN refer to its ability to convert light energy into thermal energy, and by using this it was possible to shorten the thermocycling step of RT-PCR from 1 - 2 hours to within 11 minutes. In addition, the strong magnetic property of MPN allows an external magnetic field to clear MPNs from the PCR solution to allow for fluorescent detection of the amplified genes. The nanoPCR is capable of detecting even a small amount of genes (~3.2 copies/μl) accurately while simultaneously amplifying and detecting genetic material with high sensitivity and specificity.

The researchers tested nanoPCR under clinical settings through the patient specimen tests. During the test, 150 subjects with or without COVID-19 infection were accurately diagnosed using this technology (75 positives, 75 negative samples; zero false-negatives and false-positives). The level of sensitivity and specificity was found to be equivalent to that of the conventional RT-PCR (~99%). In addition to high reliability, the whole diagnostic process was considerably fast, as on average it took about 17 minutes for the diagnosis of one specimen.

In addition, the researchers showed the possibility of improving the analytical throughput by applying a Ferris wheel system to load multiple samples at once, which would allow for simultaneous testing of many samples from multiple patients. Importantly, the nanoPCR equipment is very compact in size (15 × 15 × 18 cm) and weight (3 kg), which allows it to be portable. All of this would pave the way for rapid, decentralized testing of patients for the POC diagnosis.

"Through the improvement and miniaturization of the PCR technology, we have shown that it is possible to perform PCR based POC diagnosis in the field quickly," said Professor Cheon Jinwoo, director of CNM.

Related Links:
Institute for Basic Science

Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The AI model accurately classifies pediatric sarcomas using digital pathology images alone (Photo courtesy of Shutterstock)

AI-Driven Analysis of Digital Pathology Images to Improve Pediatric Sarcoma Subtyping

Pediatric sarcomas are rare and diverse tumors that can develop in various types of soft tissue, such as muscle, tendons, fat, blood or lymphatic vessels, nerves, or the tissue surrounding joints.... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more